Bukwang exports hipnotic-sedative emergency drug for COVID-19 related treatment

Midazolam export to Luxembourg and France completed, the United Kingdom and Chile under discussion

Bukwang announced that it has exported midazolam to France and Luxembourg for emergency use in relation to COVID-19 outbreak.

COVID-19 has continued to spread globally, resulting in the increased demand for anesthetic sedatives to alleviate pain during the treatment of COVID-19 patients. Previously in April 2020, Bukwang completed an export of midazolam injection, based upon an emergency request from the Luxembourg Trade and Investment Office.

On June 6th, Bukwang also exported 200,000 ampoules of midazolam injection to France based upon a request by the Ministry of Health. Additionally, Bukwang is currently under discussion with the British and Chile governments regarding midazolam injection supply.

Midazolam injection, which Bukwang has been exporting as an emergency drug, is a benzodiazepine-class hypnotic sedative agent which can induce sleep and reduce anxiety. Midazolam is being used to treat COVID-19 patients requiring mechanical ventilation.

Due to the spread of COVID-19 globally, drug shortage has become a serious concern. To respond to continuous requests from multiple countries for supplying midazolam injection as emergency drugs, Bukwang is committed to react as quickly as possible to fulfil the unprecedented surge in demand for this product and Bukwang is making every effort to provide maximum support in order to overcome the COVID-19 outbreak.

|    ​Korean    |